Free Trial
NASDAQ:BCLI

Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis

Brainstorm Cell Therapeutics logo
$0.70 +0.03 (+4.40%)
As of 09/19/2025 03:47 PM Eastern

About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI)

Advanced

Key Stats

Today's Range
$0.66
$0.71
50-Day Range
$0.58
$1.20
52-Week Range
$0.52
$3.96
Volume
13,975 shs
Average Volume
548,908 shs
Market Capitalization
$7.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Brainstorm Cell Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

BCLI MarketRank™: 

Brainstorm Cell Therapeutics scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Brainstorm Cell Therapeutics are expected to grow in the coming year, from ($3.01) to ($1.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Brainstorm Cell Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Brainstorm Cell Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Brainstorm Cell Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.92% of the float of Brainstorm Cell Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Brainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Brainstorm Cell Therapeutics has recently decreased by 1.61%, indicating that investor sentiment is improving.
  • Dividend Yield

    Brainstorm Cell Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Brainstorm Cell Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.92% of the float of Brainstorm Cell Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Brainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Brainstorm Cell Therapeutics has recently decreased by 1.61%, indicating that investor sentiment is improving.
  • Search Interest

    Only 1 people have searched for BCLI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.15% of the stock of Brainstorm Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 14.33% of the stock of Brainstorm Cell Therapeutics is held by institutions.

  • Read more about Brainstorm Cell Therapeutics' insider trading history.
Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BCLI Stock News Headlines

Make this AI Trade Before EOM
President Trump is set to sign a game-changing new law… That I believe will trigger a boom in a handful of artificial intelligence coins… Giving you a chance to turn a small stake into a six-figure payout.tc pixel
See More Headlines

BCLI Stock Analysis - Frequently Asked Questions

Brainstorm Cell Therapeutics' stock was trading at $2.27 at the beginning of 2025. Since then, BCLI shares have decreased by 69.2% and is now trading at $0.6995.

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) issued its quarterly earnings data on Thursday, May, 15th. The biotechnology company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by $0.07.
Read the conference call transcript
.

Brainstorm Cell Therapeutics's stock reverse split on the morning of Tuesday, October 1st 2024.The 1-15 reverse split was announced on Thursday, September 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Brainstorm Cell Therapeutics' top institutional shareholders include Gunderson Capital Management Inc. (0.26%). Insiders that own company stock include Chaim Lebovits, Stacy Lindborg and Ibrahim B Dagher.
View institutional ownership trends
.

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Brainstorm Cell Therapeutics investors own include CocaCola (KO), Organovo (ONVO), Cardium Therapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Protalix BioTherapeutics (PLX) and Isoray (ISR).

Company Calendar

Last Earnings
5/15/2025
Today
9/21/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCLI
CIK
1137883
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.62 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-519.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.21
Quick Ratio
0.21

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.36) per share
Price / Book
-0.51

Miscellaneous

Outstanding Shares
11,035,000
Free Float
8,742,000
Market Cap
$7.72 million
Optionable
Optionable
Beta
0.15

Social Links

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:BCLI) was last updated on 9/21/2025 by MarketBeat.com Staff
From Our Partners